We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Forian Inc | NASDAQ:FORA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.18 | -6.43% | 2.62 | 1.13 | 2.85 | 2.85 | 2.61 | 2.69 | 21,117 | 21:09:25 |
|
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
|
|
|
Item 1.01
|
Entry into a Material Definitive Agreement
|
Item 9.01
|
Financial Statements and Exhibits
|
(d)
|
Exhibits.
|
Exhibit No.
|
Description
|
|
Amendment 2, dated as of December 20, 2023, to License Agreement, dated as of June 19, 2019, by and between the Company and Vendor.
|
||
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
Dated: December 22, 2023
|
FORIAN INC.
|
|
By:
|
/s/ Edward Spaniel, Jr.
|
|
Name:
|
Edward Spaniel, Jr.
|
|
Title:
|
Executive Vice President, General Counsel and Secretary
|
1. |
Amendment.
|
a. |
Client agrees to a make a payment of $[***] to Company in accordance with Exhibit B for the incremental historical Licensed Data Product as described under “Project Details” in
Exhibit A (the “2014-2023 Additional Licensed Data Product”) to be delivered prior to December 31, 2023.
|
b. |
All references to the “Licensed Data” shall be replaced with “Licensed Data Product.”
|
c. |
The fourth sentence of Section 1.3 shall be amended to delete the words “and/or” before clause (v) and to include the following directly following current clause (v):
|
d. |
A Party’s exercise of its rights set forth in Section 1.4 shall be limited to one (1) time per Renewal Term.
|
e. |
Section 2.2 and all references to “Revenue Share Fees” are deleted from the Agreement and Client shall owe no further Revenue Share Fees.
|
f. |
The first sentence of Section 3 is deleted and replaced with the following:
|
g. |
Section 8.1 is revised to replace the notice information for Client and Company with the following:
|
Electronic Notice: [***] and [***]
|
Written Notice: Medical Outcomes Research Analytics, LLC
|
C/O: Forian Inc. | |
41 University Drive, Suite 400 | |
Newtown, PA 18940 |
“If to Company:
|
Written Notice: [***]
|
Attn: |
[***]
|
|
[***] | ||
[***]” |
h. |
Exhibit A is deleted and replaced with the Exhibit A attached to this Amendment 2
|
i. |
Exhibit B is deleted and replaced with the Exhibit B attached to this Amendment 2.
|
2. |
[***].
|
3. |
No Other Modification. Except as expressly amended by this Amendment 2, all other terms of the
Agreement, including prior versions and/or amendments to the SOW, shall apply and remain unchanged.
|
4. |
Amendments. Any amendments to Amendment 2 will be in writing and signed by authorized representatives
of both parties.
|
5. |
Conflicting Terms. In the event of a conflict between any of the documents consisting of the Agreement,
the terms of this Amendment 2 shall control and take precedence over such other terms of the Agreement. Otherwise, the Agreement shall remain in full force and effect.
|
6. |
Entire Agreement. This Amendment 2, together with the Agreement, represents the entire mutual agreement
of the parties and supersedes all prior agreements and understandings between the parties relating to its subject matter.
|
7. |
Counterparts. The parties may execute this Amendment 2 in counterparts, including facsimile, PDF, and
other electronic copies, which taken together will constitute one instrument. The Parties consent to the use of electronic signatures.
|
For Medical Outcomes Research Analytics, LLC: | For [***]: | ||
Signature:
|
/s/ Max Wygod | Signature: | [***] |
Print Name:
|
Max Wygod | Print Name: | [***] |
Title:
|
President
|
Title: | [***] |
Date:
|
December 20, 2023 | Date: | December 20, 2023 |
Document and Entity Information |
Dec. 20, 2023 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Dec. 20, 2023 |
Entity File Number | 001-40146 |
Entity Registrant Name | FORIAN INC. |
Entity Central Index Key | 0001829280 |
Entity Incorporation, State or Country Code | DE |
Entity Tax Identification Number | 85-3467693 |
Entity Address, Address Line One | 41 University Drive |
Entity Address, Address Line Two | Suite 400 |
Entity Address, City or Town | Newtown |
Entity Address, State or Province | PA |
Entity Address, Postal Zip Code | 18940 |
City Area Code | 267 |
Local Phone Number | 225-6263 |
Title of 12(b) Security | Common Stock, $0.001 par value |
Trading Symbol | FORA |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | true |
Entity Ex Transition Period | false |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
1 Year Forian Chart |
1 Month Forian Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions